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Obesity has become one of the leading causes of illness and mortality in the developed world. Preclinical and clinical data provide
compelling evidence for ghrelin as a relevant regulator of appetite, food intake, and energy homeostasis. In addition, ghrelin has
recently emerged as one of the major contributing factors to reward-driven feeding that can override the state of satiation. The
corticotropin-releasing-factor system is also directly implicated in the regulation of energy balance and may participate in the
pathophysiology of obesity and eating disorders. This paper focuses on the role of ghrelin in the regulation of appetite, on its
possible role as a hedonic signal involved in food reward, and on its interaction with the corticotropin-releasing-factor system and
chronic stress.
1.Introduction
Obesity and related disorders are among the leading causes
of illness and mortality in the developed world, and it
became a severe epidemic problem not only in adults
but also in younger generations [1]. To better understand
the pathophysiological mechanism that underlies metabolic
disorders, increasing attention has been paid to central regu-
latory elements in energy homeostasis, including food intake
and energy expenditure. The discovery of ghrelin and its
inﬂuence on appetite, fuel utilization, body weight, and body
composition adds yet another component to the complexity
in the central regulation of energy balance [2]. In addition,
recently it has been described that ghrelin may be implicated
in food reward [3], since ghrelin directly targets the ventral
tegmental area to increase food motivation [4]. However,
it remains to be determined whether the central ghrelin
signaling system has a role in the pathophysiology of obesity.
The corticotropin releasing factor (CRF) system is
directly implicated in the regulation of energy balance [5, 6].
In addition, it may participate in the pathophysiology of
obesity and eating disorders [7, 8]. Considerable evidence
has accumulated to demonstrate that feeding behavior is
inﬂuenced by stress. Stress triggers a physiological response
that involves the coordinated control of multiple motor,
hormonal, and vegetative systems that are engaged to
reestablish homeostasis in the face of the stress perturbation,
either real or perceived, of the internal and/or external
environment[9].Inhumanbeings,manyobesepatientstend
to eat more when they are emotionally tense or depressed
or simply bored. Sadness favored eating of high fat/sweet,
hedonically rewarding foods, whereas intake during a happy
statefavoreddriedfruit[1].Inaddition,ithasbeendescribed
that visceral overweight subjects showed stress-induced food
intake in the absence of hunger, resulting in an increased
energy intake [10].
Increasing evidence suggests an interplay between the
CRF and ghrelin systems. However, it is unknown wether
this interacion plays a role in the pathophysiology of obesity.
2.GhrelinandtheRegulationofEnergyBalance
Small synthetic molecules called growth hormone secret-
agogues (GHSs) stimulate the release of growth hormone
(GH) from the pituitary. They act through the GHS-receptor
(GHS-R), which has been cloned for diﬀerent groups [11,
12]. Despite intensive searches by diﬀerent groups, in 1999,
was puriﬁed and identiﬁed the endogenous speciﬁc ligand
for GHS-R [13]. This ligand is a molecule of 28 amino
acids called ghrelin in which the serine residue 3 was2 International Journal of Peptides
n-octanoylated.Theminimumcoreofghrelinresidinginthe
N-terminal tetrapeptide and the acylation of the peptide had
been supposed critical to cross the blood-brain barrier but
is also essential for binding the GHS-1a receptor and for its
GH releasing and other endocrine actions [13–15]. Recently,
the enzyme responsible for the acylation of ghrelin was
identiﬁed by two independent groups [16, 17]. The ghrelin
O-acetyltransferase (GOAT) is the speciﬁc acyl transferase
thatactivatesghrelin [16, 17] and belongs to the superfamily
of membrane-bound O-acyltransferases (MBOATs) [17–19].
In humans, GOAT expression is high in stomach and gut,
the major ghrelin-secreting tissues, and in the pituitary, in
which ghrelin is known to show autocrine and paracrine
eﬀects [16, 20]. GOAT is regulated by nutrient availability,
depends on speciﬁc dietary lipids as acylation substrates
and links ingested lipids to energy expenditure and body fat
mass [21]. Although devoid of neuroendocrine activity, also
unacylated ghrelin, its most abundant circulating form, is an
active molecule. This evidence agrees with the existence of
GHS-R subtypes that are activated by ghrelin independently
of its acylation [13, 22].
In humans, the stomach is a major source of circu-
lating ghrelin. It has been shown that plasma ghrelin-
like immunoreactivity levels in gastrectomized patients still
remain 35% of those in normal subjects, suggesting that
tissues other than the stomach contribute to a certain
amount of circulating ghrelin [23]. The peptide is produced
prevalently in the stomach by the X/A-like cells within
the oxyntic glands of the gastric fundus mucosa [13, 24–
27], with substantially lower amounts derived from the
bowel [24, 27–29], pancreas [28, 30], lymphocytes [28],
chondrocytes [31], kidney [28, 32], placenta [33], lung [28],
testis [28, 34], ovary [35, 36], adrenal cortex [37, 38],
pituitary (lactotrophs, somatotrophs, and thyrotrophs cells)
[39, 40], and hypothalamus [40–42].
Ghrelin is strongly involved in the regulation of energy
homeostasis. The group of Ghigo and coworkers published
for the ﬁrst time the involvement of ghrelin in the regulation
of appetite. They described that 3 out of 4 healthy volunteers
reported hunger following ghrelin administration as a “side
eﬀect” in a clinical study analyzing GH release, and this
eﬀect has been conﬁrmed in more studies [43, 44]. In
animal studies, it has been shown that ghrelin increased food
intake of rats, when it was administered either into central
nervous system or peripherally [45–47], in both satiated and
feeding conditions [48]. The i.c.v. administration generated
a dose-dependent increase in food intake and body weight
[49–51]. The time course and magnitude of this eﬀect
was similar to neuropeptide Y (NPY) [46, 49]. Also, it
has been shown a signiﬁcant increase of the food intake
after the systemic administration of ghrelin, occurring at
plasma ghrelin levels within normal fasting range [47, 52]. In
rodents, ghrelin-induced gain weight is based on accretion of
fat mass gain by reducing fat utilization, without changes in
longitudinal skeletal growth and without an increase in lean
[51].
Very low doses (30pmol) of ghrelin injected into the
arcuate nucleus (ARC) potently stimulated food intake.
Another hypothalamic nucleus that showed a similarly
prompt signiﬁcant orexigenic response was the paraven-
tricular nucleus (PVN), but the stimulation of food intake
was signiﬁcantly less than the one seen in the ARC [47].
Studies with confocal laser microscopy have analyzed the
eﬀect of ghrelin on the expression of c-fos, a marker of
neuronal activation. These studies have shown that i.p.
administration of ghrelin induces c-fos immunoreactivity in
(i) the ARC and medioparvocellular part of the PVN [52,
53], (ii) the dorsomedial and lateral hypothalamic nuclei,
and (iii) two regions of the brainstem, the nucleus of the
tractus solitarius and the area postrema [53]. In addition,
after i.c.v. ghrelin administration, c-fos immunoreactivity
was found in neuronal populations of primary importance
in the regulation of feeding, including NPY neurons, AgRP
neurons [42, 48], and orexin-containing neurons (in the
lateral hypothalamus) [53]. Furthermore, antibodies and
antagonist of NPY and AgRP abolish ghrelin-induced feed-
ing[54].GhrelinincreasesNPYandAgRPmRNAexpression
levels [42, 48–50, 55] independently of the nutritional status
[56] and blocked leptin-induced feeding reduction [48].
Furthermore, the orexigenic eﬀect of ghrelin is abolished
by i.c.v. coinjection of Y1 receptor antagonist, indicating
that ghrelin increases food intake at least partly through the
activation of the hypothalamic NPY/Y1 pathway [50, 55].
Endogenous ghrelin secretion is pulsatile and directly
related to feeding behavior [57]; after fasting, ghrelin
secretion is augmented in the form of high frequency, high
amplitude episodes [58, 59]. Ghrelin concentrations in the
blood and mRNA levels were increased by fasting and
decreased by feeding in the stomach [23, 51, 60]. The plasma
levels of ghrelin inversely correlate with body mass index
(BMI), thus, ghrelin levels are modiﬁed in patients with
anorexia nervosa and obesity. Ghrelin secretion is increased
in anorexia and cachexia, reduced in obesity, and normalized
byrecov eryofidealbodyweight[23,61,62].Theparadoxical
situation of increased basal plasma ghrelin concentrations
observed in subjects with long-term energy deﬁcit and
decreased food intake such as in restrictive anorexia nervosa
[63] suggests the existence of ghrelin resistance that may
be relevant to the decreased eﬀects of ghrelin to promote
a positive energy balance [64]. In addition, plasma ghrelin
levels regulation could be inﬂuenced by ghrelin reactive
autoantibodies (autoAbs), since it had been demonstrated
the presence of autoAbs reactive with ghrelin in healthy
subjects and rats [65, 66]. Furthermore, a role of autoAbs
against appetite-regulating neuropeptides in eating disorders
has emerged [65]. In this regard, it had been described
decreased plasma levels of acyl ghrelin IgG autoAbs present
as free or total immunoglobulins in patients with anorexia
nervosa, suggesting that altered production of ghrelin reac-
tive autoAbs is associated with persistently elevated plasma
ghrelin and eventually ghrelin resistance in anorexia nervosa
[67].
Furthermore, a negative association between body mass
and ghrelin secretion in Prader-Willi syndrome exists, where
obesity is associated with ghrelin hypersecretion [68]. In
obesehumans,foodintake(including60%ofcarbohydrates)
with postprandially increased insulin response fails to sup-
press ghrelin levels suﬃciently [69], suggesting that ghrelinInternational Journal of Peptides 3
may be involved in some of the multiple pathophysiological
mechanisms leading to obesity and type 2 diabetes [70].
The reduction in plasma ghrelin levels with high-fat diet
agreed with the low circulating levels of ghrelin in obese
humans and db/db reﬂected a physiological adaptation to
the positive energy balance associated with obesity [23, 62,
71, 72]. In addition, high-fat diet causes ghrelin resistance by
reducing NPY/agouti-related peptide (AgRP) responsiveness
to plasma ghrelin and suppressing the neuroendocrine
ghrelin axis to limit further food intake [73]. Indeed, ghrelin
secretionincreaseswithalow-proteindietanddecreaseswith
a high-fat diet [26]. It has been shown that sugar intake, but
not stomach expansion, reduced serum ghrelin levels [51].
Itisclearthatseveralmolecularmediatorsareinvolvedin
the control of energy homeostasis. This is a highly complex
process that involves several brain regions, ranging from
cortex to brainstem. However, an important eﬀort has been
paid to understand the role of hypothalamus on this process,
since numerous neural circuits involved in the homeostatic
control are located in this brain region. Discrete neuronal
populations in the hypothalamus are regulated by speciﬁc
signals of nutritional state and express neurotransmitters
that mediate particular eﬀects on food intake and/or energy
expenditure. These neuronal populations were considered
to mediate “feeding” or “satiety” responses [74]. Currently,
it seems likely that the eﬀects that are causing a positive
energy balance are mediated via leptin-responsive neurons
in speciﬁc regions of the hypothalamus [2, 48, 50]. By in situ
hybridization procedure, it has been shown that the eﬀect of
food intake on NPY neurons is mediated by the direct action
of leptin via Ob-Rb receptors expressed by these NPY cells.
The expression of these receptors is a deﬁning phenotypic
characteristic of the subset of NPY arcuate neurons that are
activated by fasting and play an adaptive response to negative
energybalance[75].Leptinreducesfoodintake,bodyweight,
and hypothalamic NPY mRNA expression, and these eﬀects
are reversed by the simultaneous administration of ghrelin
through the activation of hypothalamic NPY/Y1 receptor
pathway [48, 50, 55, 60]. However, although the leptin-
induced decrease in hypothalamic NPY mRNA expression is
completely abolished by i.c.v. coinjection of ghrelin, the sati-
ety eﬀect of leptin is only partially reversed by ghrelin. This
suggests the involvement of other orexigenic or anorexigenic
systems in the antagonism of leptin action by ghrelin [50].
Information of both anorexigenic systems, mainly
including melanocortin-derived peptides and orexigenic
peptidergic systems containing NPY and AgRP, seem to
converge in PVN [76]. Ghrelin injected peripherally induces
c-fos expression in arcuate NPY-positive neurons that
project to the medioparvocellular part of PVN [77]. Cowley
et al. showed that ghrelin is expressed in a previously
uncharacterized group of neurons in the hypothalamus.
These neurons lie in the space between the lateral, arcuate,
ventromedial, dorsomedial, and PVN hypothalamic nuclei
and they send projections to several of these nuclei as
well as outside of the hypothalamus [41]. Ghrelin boutons
established synaptic contacts on cell bodies and dendrites
of NPY/AgRP and Proopiomelanocortin (POMC) neurons
in the arcuate nucleus. Also, ghrelin boutons were in direct
appositiontoNPYandGABAaxonterminalsintheARCand
PVH. In the paraventricular hypothalamic nucleus (PVN),
some of ghrelin axons innervated CRF cells [70, 78, 79].
Therefore, the ﬁnal eﬀects of ghrelin are likely to reﬂect
complex interactions of GHRH, CRF, AVP, NPY, and other
hypothalamic neuronal circuits [80].
In addition, it has been recently described that ghrelin
is implicated in certain rewarding aspects of eating that are
separated from eating-associated body weight homeostasis
and that require the presence of intact orexin signaling [81].
Growth hormone secretagogue receptors are expressed in
tegmental and mesolimbic areas, such as the ventral tegmen-
tal area (VTA) and laterodorsal tegmental areas (LDTg),
involved with reward processing [82]. Ghrelin binds to
neuronsinVTA,whereincreasesdopamine neuronalactivity
and dopamine turnover in the nucleus accumbens [83]. The
neurotransmitter dopamine is of primary importance for
incentive motivation [3]. Furthermore, ghrelin signaling at
the level of the VTA appears to be important for feeding
eﬀects as intra-VTA injection of ghrelin increases the intake
of palatable food [84].
3. CRF Components andthe Regulation of
EnergyHomeostasis
The mammalian CRF family comprises several peptides
such as CRF, urocortin (Ucn), UcnII, and UcnIII [85]. In
addition to integrate endocrine and autonomic and behav-
ioral responses to stress via activation of the hypothalamic-
pituitary-adrenal (HPA) axis [86, 87], considerable evidence
suggests a role for the CRF system in the regulation of energy
balance [88]. In recent years, vast new endogenous functions
have been attributed to this family, including regulation
of food intake and satiety, gastrointestinal motility, vascu-
lar tone and development, hearing, and cardiac function,
demonstrating the ubiquitous importance of the CRF family
[89].
The CRF system is involved in energy homeostasis via
direct central actions independent of HPA axis control
[90], with dysfunctions of CRF system hypothesized to
participate in the pathophysiology of obesity and eating
disorders [7, 10, 91]. Most pharmacological data concerning
the regulation of energy balance by the CRF system have
been obtained during acute administration of CRF and Ucns
which dose-dependently inhibits food intake [5]. However,
whereas central administration of CRF has an eﬀect on
feeding behavior that is rather short (1–6h) in duration,
central administration of Ucn has an eﬀect that persists
12 or 24 hours [92]. In addition, urocortin was found to
have the most potent and prolonged inhibitory eﬀect on
decreasingfoodintakeamongtheCRFfamilypeptides,when
administered peripherally [93, 94]. Also Ucn II and Ucn III
play an important role in regulating food intake [94, 95].
Furthermore, the feeding stimulatory eﬀect of NPY is
attenuated by administration of CRF [88]. Diﬀerent studies
suggests that CRF is a hypothalamic regulatory factor that
inhibits feeding induced by NPY [88, 96]. I.c.v. pretreatment
with a CRF receptor antagonist, α-helical CRF [9–41],
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CRF systems attenuate intake under conditions of evoked
appetite [88, 96].
In addition to energy intake, there is evidence that
CRF and Ucn also aﬀect energy expenditure. Chronic
administration of CRF and Ucn dose-dependently decreases
body weight, with a great impact of CRF [94]. Acute
administration of CRF activates the sympathetic nervous
system (SNS), brown fat tissue (BAT) thermogenesis [5, 97],
elevates norepinephrine release in several brain areas [98,
99], increased uncoupling protein-1 in BAT [100], increases
body temperature [101], and reduces carcass fat [6]. In this
regard, central infusion of CRF induces a state of negative
energy balance that is partially a function of its eﬀects on
foodintakeandpartiallyafunctionofitsactivatingeﬀectson
the sympathetic nervous system. In contrast, UCN appears
toinducealessdramatic stateofnegativeenergybalancethat
is primarily dependent on changes in food intake and does
not appear to involve sympathetic nervous system activation
[102]. Consistent with this idea, brown adipose fat pad
weights and adrenal tissue weights increased in CRF-treated
rats. Furthermore, chronic central administration of CRF
resulted in elevated corticosterone, cholesterol, triglycerides,
and free fatty acids (FFA), all of those suggesting SNS-
induced lipolysis. When a selective antagonist of the CRFR2
receptor, antisauvagine-30 (ASV-30), was administrated,
it could clearly attenuated the eﬀects of both UCN and
CRF on food intake, but it did not aﬀect the SNS or
HPA variables that were altered by chronic CRF-infusion.
Interestingly, ASV-30 alone also increased food intake and
glucose levels, providing the evidence that antagonism of
endogenous CRF can result in increased feeding [102]. The
eﬀects of the urocortin on the microstructure of ingestive
behavior are analogous to those of the dexfenﬂuramine, a
serotoninergic agonist which suppresses appetite. Anorexic
and thermogenic properties of serotonin receptor agonist
have been shown to be dependent on brain [88].
The distribution and regulation of both known subtypes
of CRF receptor, CRFR1, and CRFR2 further support the
relevance of brain CRF systems in energy balance regulation.
In particular, CRFR1 receptor are broadly distributed in
brain with high densities observed in cortical and limbic
regions relevant for regulation of hypophysiotropic secretion
and sympathetic outﬂow mediated by brainstem autonomic
nuclei, and the CRF2 receptors are focally distributed with
high densities in subcortical regions such as the olfactory
bulb,lateralseptum,andventromedialhypothalamus.More-
over, levels of protein and message for CRF itself and both
CRF receptors are altered by experimental conditions such
as anorexic drug treatment or fasting which disturbs energy
homeostasis [88].
Experiments conducted in rats have suggested that
paraventricular hypothalamic nucleus is the site of the
anorexic eﬀect, but the observations that PVH lesions do
not prevent the CRF-mediated anorexic eﬀects are consistent
with the view that the anoretic actions of CRF and urocortin
can be exerted at extra PVH sites. The chronic infusion
of urocortin into the arcuate-ventromedial region causes
anorexia suggests that both the ventromedial hypothalamic
nucleus, which express the CRFR2, and the arcuate nucleus,
which express CRFR1, can be sites of the anorectic eﬀects of
CRF-related peptides [88].
Several lines of evidence indicate that CRF-induced anx-
iogenic eﬀects, ACTH secretion, and locomotor activation
are mediated by the activation of CRF receptor type 1
[103, 104]. Bradbury et al. have reported that stress-induced
anorexia may involve stimulation of CRFR1 during the ﬁrst
hours of the response; a similar reduction in the amount
of food and water consumed following the treatment with
urocortin was observed in CRFR1 KO mice [105]. Moreover,
a decrease in food-water intake was observed in CRFR1
KO and wt mice following i.c.v CRF treatment [103]. In
addition, CRFR1 KO mice appear to exhibit normal food
intake over a 24h period relative to wild-type controls,
further suggesting that receptors in brain other than CRFR1
regulate normal food intake [106]. CRFR2 may mediate the
appetite-suppressing eﬀectsofCRF-like peptides [103],since
the selective downregulation of CRFR2 mRNA with an anti-
sense oligonucleotide attenuates CRF-induced anorexia. The
demonstration that expression of the CRFR2 gene is reduced
in obese, diabetic, and food-deprived rats and increased
following i.c.v. infusions of leptin is also consistent with a
role for the CRFR2 in the regulation of energy balance [88].
T h er o l eo fC R F R 2r e c e p t o ri ne n e r g yb a l a n c em a y
primarily mediate the appetite suppressing eﬀects of CRF
rather than the metabolic eﬀects of this peptide [102].
Genetic deletion of CRF2 receptors increased food intake
duringthedarkphaseofthelight/darkcycle.Microstructural
analyses indicated that this orexigenic eﬀect was due to
increased meal size. CRF2 pathway endogenously reinforces
the satiating value of food at the circadian time of greatest
spontaneous intake. This suggests that the CRF2 pathway
might be involved in the processing of gut-derived satiation
signals or might potentiate their action [107, 108].
Studies conducted in the rat suggest that CRFergic activ-
ity is reduced in obesity and food-deprived rats [109]. The
obeseZuckerratismoresensitivethanitsleancounterpartto
theeﬀectsofacentralinfusionofCRF[85].Thereisevidence
that the expression of CRF-binding protein (CRF-BP) is
reduced in the medial preoptic area and the basolateral
complex of the amygdala in obese and food-deprived rats. In
addition, obesity and food deprivation reduce the expression
of CRFR2 receptor mRNA within the VMH [88]. In fact,
obese rodents readily react to stressful and food deprivation
which can even induce, in genetically obese animals, a
neurogenic-stress-like response that strongly stimulates the
CRF system. Nonetheless, there are adaptations of the CRF
system in obesity (or following food deprivation). Food
deprivation could concur to reduce the CRF tone [85].
However, there is increasing evidence that, in humans,
abdominal obesity phenotype may be characterized by a
hyperactivation or hyperresponsiveness of the HPA axis
[110]. In the Cushing syndrome, hypercortisolism results in
abdominal obesity [109].
3.1.StressResponse: Activationof theHypothalamic-Pituitary-
Adrenal Axis and Glucocorticoids (Gcs) Feedback. Stress trig-
gers a physiological response that involves the coordinated
control of multiple motor, hormonal, and vegetative systemsInternational Journal of Peptides 5
that are engaged to reestablish homeostasis in the face
of the stress perturbation, either real or perceived, of the
internal and/or external environment. The neuroendocrine
component of the stress response is characterized by the
activation of the hypothalamic-pituitary-adrenal axis which
resultsinhighlevelsofglucocorticoidsintheblood[6,9,10].
The resulting stress levels of circulating glucocorticoids
give rise to multiple, complex physiological eﬀects with
highly variable kinetics throughout the whole organism,
including eﬀects on glucose metabolism and mobilization
in diﬀerent tissues, regulation of immune and inﬂammatory
responses, cardiovascular eﬀects, neuroendocrine actions,
and eﬀects on cognition [9].
A main feedback eﬀect of glucocorticoids is to suppress
the activation of the HPA axis, inhibiting HPA hormone
secretion and precipitating the termination of the neuroen-
docrine stress response. These inhibitory feedback eﬀects on
HPA axis activation are thought to occur in the hippocam-
pus, the hypothalamus, and the pituitary gland [9, 111].
Acutely, glucocorticoids increase utilizable energy by
promoting glycogen and protein metabolism in liver and
muscle, respectively, along with enhancing catecholamine-
induced lipolysis in adipose tissue [112].
Acutely (within hours) glucocorticoids directly inhibit
further activity in the hypothalamo-pituitary-adrenal axis,
but the chronic actions (across days) of these steroids on
brain are directly excitatory. Chronically high concentrations
of Gcs act in three ways that are functionally congruent. (i)
Gcs increase the expression of CRF mRNA in the central
nucleus of the amygdala, a critical node in the emotional
brain. CRF enables recruitment of a chronic stress-response
network. (ii) Gcs increase the salience of pleasurable or com-
pulsive activities (ingesting sucrose, fat, and drugs, or wheel-
running). This motivates ingestion of “comfort food.” (iii)
Gcs act systemically to increase abdominal fat depots [113].
As glucocorticoids increase, insulin secretion also
increases, as it is well known from the strong association
of Cushing’s syndrome with type 2 diabetes. It appears that
insulin plays a profound role in food selection whereas Gcs
determine the motivation for selecting these foods, perhaps
thought their actions on dopamine secretion in the nucleus
accumbens [1].
4.GhrelinandCRFSystem
Ghrelin and CRF have opposed functions in the control
of food intake. Ghrelin is a hunger signal, released by the
stomach into the circulation and produced in a subset of
hypothalamic neurons [70]. Its secretion is triggered to
counteract further deﬁcit of storage and to prevent starva-
tion. CRF causes anorexia and also activates the sympathetic
nervous system in addition to its role as a major regulator of
the hypothalamic-pituitary-adrenal axis [114].
However, increasing evidence suggests an interplay
between the CRF and ghrelin systems. Ghrelin expression
is present in aﬀerents to CRF-expressing neurons [41]. In
addition,peripheralandi.c.v.ghrelininjectionincreasesCRF
mRNA expression in vivo in the hypothalamus of rats [115]
and mice [116] in vitro [82]“ in vivo”a n d“ in vitro”, in the
hypothalamus of rats and mice [85, 112, 116]a n dh a sa
potent ACTH-releasing activity [43]. Functional interactions
between these systems in the control of gastrointestinal
motility [116] have been demonstrated. In addition, ghrelin
has anxiety-like eﬀects [117–119].
Furthermore, the CRF system interacts with ghrelin.
Following acute stress, a rise in either gastric ghrelin mRNA
or total plasma ghrelin has been observed, also tail pinch
stress signiﬁcantly increased ghrelin mRNA expression
[116, 120], although, recently, it has been demonstrated
that increasing ghrelin through caloric restriction decreases
anxiety and depressive-like behavior via GHS-R1a signaling
[119].
Indeed, Ucn increased acylated and desacylated ghrelin
levelsinthegastricbodyanddecreasedtheirlevelsinplasma,
and decreased preproghrelin mRNA levels in the gastric
body. In addition, Ucn-induced reduction of plasma ghrelin
a n df o o di n t a k ew e r er e s t o r e db yC R F R 2b u tn o tC R F R 1
and Ucn-induced reduction of food intake was restored by
exogenous ghrelin [91].
Endogenously as well as exogenously induced hypercor-
tisolism leads to a signiﬁcant decrease in plasma ghrelin
levels in humans, indicating a possible feedback mechanism
betweengastricghrelin secretion andtheactivitylevelsofthe
HPA [121].
Within the brain, the expression of GHS-R1a is remark-
ably high in the hypothalamus-pituitary unit, in agreement
with its impact on anterior pituitary function as well as
with its inﬂuence in the control of appetite, food intake, and
energy balance [61, 82]. But, mRNA encoding the GHS-R
was also expressed in several other discrete regions of the
brain (rat), such as dentate gyrus, CA2 and CA3 regions of
the hippocampal formation, thalamic regions, and several
nuclei within the brainstem including pars compacta of
the substantia nigra, ventral tegmental area, median and
dorsal raphe nuclei, Edinger-Westphal nucleus, laterodorsal
nucleus, and facial nerve [82]. It looks like that a relationship
between ghrelin and the CRF system exists, since ghrelin
receptorhasbeendetectedintheparaventricularnucleus,the
principal source of CRF, and in the Edinger-Westphal nuclei,
the primary site of urocortin expression.
4.1. Brain Circuitry in the Hypothalamus: Connecting Ghrelin.
Ghrelin activates Agrp/NPY neurons, thereby stimulating
f o o di n t a k e .G H Sr e c e p t o rm R N Ai se x p r e s s e di n9 4 %
of arcuate neurons that express NPY [122]. The ARC-
NPY/Agrp neurons project dorsally and anteriorly into
the perifornical lateral hypothalamic area, paraventriculat
nucleus, dorsomedial nucleus of the hypothalamus, and
medial preoptic area [74]. NPY projections to the PVH
are derived from the arcuate nucleus and the brainstem,
and synaptic contacts between NPY terminals and CRF
neurons have been demonstrated. Available pharmacological
evidence suggests that NPY exerts a stimulatory eﬀect on
CRF neurons. It is possible that under normal conditions,
brief activation of the ARC NPY system might not only
trigger a feeding response, but also activate counteracting
mechanism as the CRF system [123]. Although no con-
vincing Y1 receptor staining wasfound in CRF cell bodies,6 International Journal of Peptides
Y1-positive ﬁbers made close appositions on CRF cell bodies
in the parvocellular nucleus as well as in the periventricular
zone. So, NPY may be able to indirectly modulate CRF
neuronal activity by acting on presynaptic Y1 receptors to
modulate the secretion of neurotransmitters or neuromodu-
lators, which in turn modulate CRF neuronal activity [123].
The group of Smith has discovered the presence of CRFR1
colocalized to NPY neurons in the ARC, and it provided a
potential neuroanatomical circuit by which CRF may inhibit
NPY signaling by direct modulation of NPY neurons [124].
One possible eﬀect of ghrelin is to increase the release of
NPY onto GABAergic nerve terminals, disinhibiting the CRF
neuron and thus stimulating greater CRF release into the
pituitary-hypophyseal portal circulation, driving increased
ACTH secretion from the pituitary [41]. The CRF receptor
antagonist α-helical CRF9-41 signiﬁcantly inhibited ghrelin-
induced anxiogenic eﬀects, so this behavior eﬀect includes a
mechanism of action involving CRF [116].
5. Stress andObesity:Ghrelinas
aH ed o nicS ignal ?
5.1. Reward System and the Control of Food Intake. Reward
is often conceptualized as if it were a single psychological
process or a unitary feature of a reinforcing stimulus. It is
sometimes identiﬁed with the pleasure or hedonic impact of
a stimulus and is viewed by some as necessarily subjective in
nature. However, reward is not a unitary process, but instead
a constellation of multiple processes many of which can be
separately identiﬁed in behavior, especially after the compo-
nent processes are dissociated by brain manipulations [125].
Certain foods, particularly those rich in sugars and fat,
are potent rewards that promote eating [126, 127]a n d
triggered learned associations between the stimulus and
the reward (conditioning) [128]. Several neurotransmitters,
including DA, as well neuropeptides involved in homeostatic
regulation of food intake, are implicated in the rewarding
eﬀects of food. Dopamine is a key neurotransmitter mod-
ulating reward, which it does mainly through its projections
from the ventral tegmental area (VTA) [128].
The VTA dopamine (DA) projection to nucleus accum-
bens (NAcc) has been implicated in the control of behaviors
motivated by rewards [129–131]. The VTA also contains
DA neurons that project to medial prefrontal cortex (PFC),
a structure linked functionally to temporal organization of
goal-directed behaviors [131].
The mesolimbic dopamine projections, originating from
neuronal cell populations in the VTA and terminating in
the ventral striatum and the prefrontal cortex, are linked
to anticipatory, appetitive, or approach phases of motivated
behaviorandareimportantforanticipatoryfoodrewardand
food-seeking behavior [132].
The extensive glutamatergic aﬀerents to DA neurons
from regions involved with sensory (insula or primary gus-
tatory cortex), homeostatic (hypothalamus), reward (NAc),
emotional (amygdala and hippocampus), and multimodal
(orbifrontal cortex (OFC) for salience attribution) modulate
their activity in response to rewards and to conditioned cues
[128, 133]. Speciﬁcally, projections from the amygdala and
the OFC to DA neurons and NAc are involved in conditioned
responses to food [128, 134].
5.2. Ghrelin as a Hedonic Signal? Chronic stress induces
changes in mood, feeding, and metabolism by a poorly
understood neurobiological mechanism. Elevated stress hor-
mones and palatable food intake and the consequent accre-
tion of fat can serve as feedback signals that reduce perceived
stress, thus reinforcing stress-induced feeding behavior [1].
Stress not only increases glucocorticoid levels through
the cellular actions of CRF in the hypothalamic-pituitary-
adrenal axis, but also induces the release of CRF in extrahy-
pothalamic brain regions, such as VTA [135, 136], where
stimulates CRFR1 on VTA dopamine neurons and activates
a protein-kinase-C- (PKC-) dependent enhancement of Ih,
which led to increased cell ﬁring [137]. This activation may
be implicated in the interaction between stress, dopamine,
and motivation which is important for many behaviors and
psychiatric disorders such as depression [138–140]d r u g
abuse [136, 141], and schizophrenia [138, 142].
Ghrelin has recently emerged as one of the major con-
tributing factors to reward-driven feeding that can override
the state of satiation [3, 81, 84, 143]. The ghrelin receptor,
GHS-R1A, is also expressed in tegmental and mesolimbic
areas involved in reward, such as the VTA and laterodorsal
tegmental areas (LDTg). Intracerebroventricular injection
of ghrelin has been shown to stimulate food intake [144],
especially the intake of palatable food [84]. Moreover, the
eﬀects of peripheral ghrelin on food intake were blunted by
intra-VTA administration of a GHS-R1A antagonist [83].
Consistent with this, peripheral treatment with a GHS-
R1A antagonist decreased preference for palatable food,
suppressed the ability of sweet treats to condition a place
preference [84], and suppressed motivated behavior for
rewarding foods, both sweet [3, 84, 143] and high-fat
foods [81]. Collectively these data support the idea that
the physiological role of ghrelin is to increase the incentive
motivation for natural rewards such as food.
The central ghrelin signaling system emerges as a novel
and interesting therapeutic target as studies in rodents have
shown that ghrelin antagonists suppress the mesoaccumbal
dopamine system, suppress the intake of (and preference
for) palatable food, suppress the ability of rewarding foods
to condition a place preference, and decrease operant
responding for rewarding foods [3]. The CRF system is
directly implicated in the regulation of energy balance [5, 6]
and may participate in the pathophysiology of obesity and
eating disorders. Additionally, increasing evidence suggests
an interplay between the CRF and ghrelin systems. Further
studies should determine whether ghrelin plays a role in the
feeding behavior associated with stress.
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